Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer
-
Published:2023-06
Issue:
Volume:69
Page:330-341
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Licata LucaORCID, Mariani Marco, Rossari Federico, Viale Giulia, Notini Giulia, Naldini Matteo Maria, Bosi Carlo, Piras Marta, Dugo Matteo, Bianchini GiampaoloORCID
Subject
General Medicine,Surgery
Reference140 articles.
1. The future of immune checkpoint therapy;Sharma;Science,2015 2. New strategies in breast cancer: immunotherapy;Pusztai;Clin Cancer Res,2016 3. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs;Bianchini;Nat Rev Clin Oncol,2022 4. Role of immunotherapy in breast cancer;Jacob;JCO Oncology Practice,2023 5. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20. PMID: 30345906.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|